How the price of AstraZeneca's buyout of CinCor fell by $1.4B
CinCor scored a $1.8 billion buyout deal with AstraZeneca earlier this month, but according to recently released documents, it almost walked away from the deal table with much more than that.
In September, AstraZeneca offered to buy CinCor for $60 per share plus a contingent value right of $6 per share, adding up to $3.2 billion if all milestones had been achieved, according to an SEC filing published on Monday. However, the CinCor board and CEO Marc de Garidel wanted to see more cash upfront.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.